Trikafta, elexacaftor/tezacaftor/ivacaftor

About Trikafta

Trikafta (elexacaftor, tezacaftor, and ivacaftor) is manufactured by Vertex Pharmaceuticals and was approved by the US FDA in October 2019 for patients with cystic fibrosis aged twelve years and older who have at least one F508del mutation in the CFTR gene. The label has since been extended down to children aged two and older, and to a broader range of responsive CFTR mutations. In several major markets, Trikafta is marketed as Kaftrio.

Cystic fibrosis is a genetic disease that affects the lungs, pancreas, sinuses, intestines, and reproductive system. For many patients, Trikafta is the first therapy that addresses the underlying CFTR defect rather than just the downstream complications. Reserve Meds coordinates US-sourced Trikafta for international patients through a documented named-patient pathway with full DSCSA serial traceability, prioritizing destination countries where Trikafta is not yet locally reimbursed or registered.

How Trikafta works

Trikafta is a CFTR modulator. CFTR is a protein channel that sits on the surface of many cells and moves chloride and bicarbonate ions across the cell membrane. In cystic fibrosis, mutations in the CFTR gene produce a protein that either does not fold properly, does not reach the cell surface, or does not open and close as it should. The result is thick, sticky mucus that obstructs the airways and pancreatic ducts and creates a cycle of infection and inflammation.

Trikafta is a triple combination. Elexacaftor and tezacaftor are CFTR correctors, which help the defective CFTR protein fold properly and reach the cell surface. Ivacaftor is a CFTR potentiator, which increases the time the channel stays open once it is in place. Together, the three molecules restore meaningful CFTR function for patients with at least one F508del mutation, which is present in roughly ninety percent of people with cystic fibrosis. Most patients on Trikafta experience improvements in lung function as measured by FEV1, fewer pulmonary exacerbations, better weight gain, and a sharp drop in sweat chloride.

FDA indications

• Cystic fibrosis in patients aged two years and older who have at least one F508del mutation in the CFTR gene, or another mutation in the CFTR gene that is responsive based on in vitro or clinical data.

Dosing and route

Trikafta is taken orally, twice a day, with fat-containing food. Fat is required for absorption, so the dose is usually paired with a meal or snack that contains a meaningful amount of fat such as butter, oil, nuts, eggs, dairy, or avocado. Standard adult dosing is two orange tablets in the morning (each containing 100 mg elexacaftor, 50 mg tezacaftor, and 75 mg ivacaftor) and one blue tablet in the evening (containing 150 mg ivacaftor). Pediatric dosing is weight-based, with reduced-strength tablet and granule formulations available for younger patients.

Dose adjustments are required when Trikafta is co-administered with strong or moderate CYP3A inhibitors such as certain antifungals, antibiotics, and protease inhibitors. Strong CYP3A inducers such as rifampin should generally be avoided because they reduce Trikafta exposure significantly. The treating physician will check liver function tests before starting and periodically during treatment.

Common side effects

The most frequently reported side effects include headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, increased liver enzymes (ALT and AST), nasal congestion, increased blood creatine phosphokinase, rhinorrhea, rhinitis, influenza, sinusitis, and increased blood bilirubin. Most side effects are mild to moderate and manageable. Serious but less common risks include elevations in transaminases that may require dose modification or discontinuation, drug interactions affecting hormonal contraception, lens opacities (cataracts) particularly in pediatric patients, and rare cases of mental health changes including depressed mood. Periodic ophthalmologic examinations are recommended in children and adolescents starting Trikafta.

Cross-border named-patient access

Reserve Meds operates a named-patient program for Trikafta. The pathway is built for international patients who have a valid prescription from a treating physician in their home country and want a US-sourced, DSCSA-traceable supply shipped to them on a documented regulatory pathway. We do not stock inventory, we do not ship without a prescription, and we do not operate inside the US prescription market. Every shipment is patient-specific, physician-authorized, and routed through a US specialty wholesaler with full serialization on every unit.

Reserve Meds does not replace the relationship with a treating physician. We coordinate the supply leg, the documentation leg, and shipping. The clinical leg, including CFTR genotype confirmation, baseline liver function testing, ophthalmologic monitoring in children, and ongoing dose decisions, stays with the patient's pulmonologist or cystic fibrosis specialist in the destination country. Trikafta is a chronic therapy taken every day for life, so continuity of supply and continuity of clinical follow-up are equally important.

How Reserve Meds coordinates Trikafta

1. Patient or treating physician submits a named-patient request, including CFTR genotype documentation.
2. Clinical team verifies appropriateness of Trikafta for the patient and destination country.
3. Treating physician issues prescription and clinical justification.
4. Country-specific NPP or personal-import documentation is prepared.
5. Trikafta is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
6. Shipment is coordinated to the patient's physician or hospital pharmacy. Trikafta is stable at room temperature up to thirty degrees Celsius, so cold-chain is not required, but tamper-evident packaging and serial integrity are maintained end to end.